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Abstract  
 
 
 Prostate cancer (PCa) is one of the most common male malignancies 
worldwide and a leading cause of cancer-related mortality. Phenotypical and functional 
heterogeneity which characterizes this disease could be explained by genetic and 
epigenetic alterations together with a subpopulation of cells present in tumor bulk, the 
prostate cancer stem cells (PCSCs). This rare subpopulation has been linked with high 
tumorigenicity and, in fact it was suggested to be the driving force underlying tumor 
formation, progression, metastatic spread and therapy resistance, culminating in the 
lethal forms of PCa. Several studies tried to isolate this subpopulation within the tumor, 
however the techniques employed for this purpose and the ideal combination of 
surface markers used to select PCSCs are still controversial.  
The main objective of this dissertation was to identify and isolate the potential 
PCSC population in PCa cell lines and primary prostate tumors, using flow cytometry, 
based on the expression of a combination of cell surface markers, EpCAM+/CD24-
/CD44+/α2β1
high/CD49f+. To achieve that goal, the expression of these markers was 
firstly assessed in PCa cell lines, which revealed a homogeneous expression of all 
markers and, therefore, no specific populations could be discriminated by flow 
cytometry. However, it was apparent that more aggressive/metastatic PCa cell lines 
displayed a higher staining intensity for those markers, suggesting that their abundance 
in PCa cell cultures is correlated with the malignant phenotype. This was further 
confirmed at mRNA level, not only for the expression of those genes but also for some 
pluripotency-associated genes. A strong inversely correlation was found between 
CD44 and AR (r = -0.76, p < 0.0001), with an increase in CD44 expression in the 
castration-resistant PCa cell lines. Likewise, α2β1 and CD49f exhibited the same 
expression pattern with a strong positive correlation (r = 0.80, p < 0.0001). 
As surface markers expression levels are not exclusively linked to the CSC 
phenotype, another technique to isolate CSCs, based on the intrinsic intracellular 
autofluorescent phenotype of the putative CSCs was used. We, thus, identified and 
segregated a small population of putative CSCs in VCaP and PC-3 cell lines (2.03% 
and 1.02%, respectively). Nevertheless, when these cells were analyzed for gene 
expression, no stemness characteristics were apparent. 
Finally, the EpCAM+/CD24-/CD44+/α2β1
high/CD49f+ expression phenotype was 
assessed in primary tumors as well as in the respective normal adjacent tissue (NPT), 
using flow cytometry. All the analyzed samples (either tumor or NPT) exhibited a 
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considerable pleomorphism and based on the selected markers no specific populations 
could be separated. Nevertheless, the efficiency of the technique was confirmed, once 
the leukocyte population was clearly identified and isolated. Globally, the surface 
markers were significantly more expressed in NPT than in the tumor counterpart. CD44 
showed a trend for higher expression in the tumors with lower Gleason score (GS=7). 
At mRNA level, a strong positive correlation between α2β1 and CD49f (r = 0.75, p < 
0.0001) was depicted, as previously observed in cell lines. 
We concluded that the EpCAM+/CD24-/CD44+/α2β1
high/CD49f+ panel is unable to 
define a PCSC population either in vivo or in vitro. Further studies are now mandatory 
to evaluate not only other potential PCSCs markers, but also to study the population 
separated by intracellular autofluorescence. The identification of a PCSC 
subpopulation would be of ultimate importance as it might contribute to the 
development of novel target therapies designed to fight advanced PCa. 
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Resumo  
 
 
 O cancro da próstata é uma das doenças malignas mais comuns a nível 
mundial, e associa-se com elevada mortalidade, sobretudo na doença avançada. Esta 
doença é caracterizada por heterogeneidade fenotípica e funcional, que pode ser 
explicada pelas alterações genéticas e epigenéticas que a caracterizam e pela 
presença de uma subpopulação de células que está presente no tumor, denominada 
por células estaminais do cancro da próstata. Esta é uma subpopulação rara no tumor 
que tem vindo a ser associada com uma elevada tumorigenicidade. De facto, esta 
população é apontada como a responsável pela formação e progressão do tumor, 
assim como pela formação de metástases e resistência à terapia, culminando nas 
formas letais da doença. Vários estudos tentaram isolar esta subpopulação a partir da 
massa tumoral, no entanto quer as técnicas utilizadas para esse fim como a 
combinação dos marcadores de superfície a utilizar são, ainda, bastante controversas. 
 Consequentemente, o principal objectivo desta Dissertação foi identificar e 
isolar a potencial população de células estaminais do cancro da próstata em linhas 
celulares e tumores primários, através de citometria de fluxo, com base na 
combinação da expressão dos seguintes marcadores de superfície celular: 
EpCAM+/CD24-/CD44+/α2β1
high/CD49f+. De forma a atingir este objectivo, a expressão 
destes marcadores de superfície foi avaliada nas linhas celulares de cancro da 
próstata, que revelaram uma expressão homogénea de todos os marcadores, não 
sendo possível, portanto, identificar populações específicas por citometria de fluxo. No 
entanto, foi possível observar que as linhas celulares mais agressivas e metastáticas 
apresentaram uma intensidade de marcação superior dos marcadores referidos, o que 
sugere que a abundância dos mesmos nas linhas celulares de cancro da próstata está 
correlacionada com o fenótipo maligno. Isto foi posteriormente confirmado a nível de 
mRNA, não só para a expressão destes genes mas também de outros genes 
associados com a pluripotência. Foi registada uma forte correlação inversa entre a 
expressão de CD44 e AR, sendo que houve um aumento na expressão de CD44 nas 
linhas celulares resistentes à castração. Da mesma forma, α2β1 e CD49f 
demonstraram o mesmo padrão de expressão, apresentando uma forte correlação 
positiva (r = 0.80, p < 0.0001). 
 Uma vez que os níveis de expressão dos marcadores de superfície não estão 
exclusivamente relacionados com o fenótipo de células estaminais do cancro, foi 
utilizada outra técnica para isolar estas células, com base no fenótipo intrínseco de 
 viii 
 
autofluorescência intracelular que as putativas células estaminais apresentam. Foi, 
assim, possível identificar e separar uma pequena população de possíveis células 
estaminais do cancro nas linhas celulares VCaP e PC-3 (2.03% e 1.02%, 
respetivamente). Contudo, quando analisadas para a expressão dos seus transcritos, 
estas populações não revelaram propriedades associadas com a estaminalidade.  
 Por fim, foi avaliada a expressão do fenótipo EpCAM+/CD24-
/CD44+/α2β1
high/CD49f+ em tumores primários, assim como no respetivo tecido normal 
adjacente, por citometria de fluxo. Todas as amostras analisadas (tecido normal e 
tumor) exibiram um acentuado pleomorfismo. Adicionalmente, e com base nos 
marcadores selecionados não foi possível separar subpopulações específicas. No 
entanto, foi possível confirmar a eficiência da técnica, já que a população de leucócitos 
foi claramente identificada e isolada. Globalmente, houve uma expressão 
significativamente superior dos marcadores no tecido normal do que no tumor. A 
expressão de CD44 mostrou uma tendência para ser superior nos tumores com um 
Gleason score mais baixo (GS=7). A nível de mRNA, também foi detetada uma forte 
correlação positiva entre o α2β1 e CD49f (r = 0.75, p < 0.0001), tal como já tinha sido 
observado nas linhas celulares. 
 Em conclusão, o painel EpCAM+/CD24-/CD44+/α2β1
high/CD49f+ não se revelou 
eficiente na identificação de subpopulação de células estaminais nas amostras 
analisadas. Mais estudos são necessários, de maneira a avaliar não só outros 
potenciais marcadores de células estaminais do cancro da próstata, mas também para 
estudar a população separada com base na autofluorescência intracelular. A 
identificação de uma subpopulação de células estaminais do cancro da próstata seria 
de extrema importância, no sentido de contribuir para o desenvolvimento de terapias 
alvo para o combate ao cancro da próstata avançado.  
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General Introduction 
 
 
 
PROSTATE CANCER 
 
Prostate Pathology 
 Prostate disorders comprise several benign and malignant conditions and are 
commonly found in elderly men. The most common are benign prostatic hyperplasia, 
prostatic intraepithelial neoplasia and prostate adenocarcinoma [1]. 
 Benign prostatic hyperplasia (BPH) is the most common nonmalignant 
condition, found in more than 50% of older men [2]. BPH is a chronic condition often 
arisen from the transition zone of the prostate, and is characterized by a cellular 
proliferation of the epithelial and stromal elements of the gland. This condition leads to 
prostatic enlargement which in turns generates resistance in the urethra, causing lower 
urinary tract symptoms [2]. In the great majority of the cases it is not considered as a 
pre-neoplastic lesion. 
 Prostatic intraepithelial neoplasia (PIN) lesions are characterized as cytological 
atypia of the lining epithelium of prostatic ducts and acini. These lesions are frequently 
multifocal, predominantly located in the peripheral zone and are associated with 
progressive phenotypic and genotypic alterations, which are intermediate between 
benign epithelium and cancer. Several studies point PIN as a precursor lesion of 
prostate adenocarcinoma (PCa) [3]. 
 
Prostate Adenocarcinoma 
The adenocarcinoma of the prostate is a highly heterogeneous disease, both in 
terms of pathology as in clinical presentation. Multiple tumor foci with different 
histological characteristics are frequently seen in the same gland [4, 5]. Furthermore, 
many tumors at the same stage that are considered to be histologically identical lead to 
different clinical outcomes, ranging from latent to highly aggressive PCa [6]. Below are 
summarized the most relevant features of PCa. 
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Epidemiology 
PCa is the second most common cancer diagnosed in men worldwide, 
accounting for 15% of total newly diagnosed cancers (Figure 1) [7]. Almost 70% of the 
cases occur in more developed regions (Figure 2) [7]. In Portugal, PCa is the most 
common neoplasia among men, with 6,622 new cases detected in 2012 and the third 
cause of cancer related mortality (11.1% of total cancer cases). PCa incidence rates 
differ considerably worldwide; the highest rates are registered in Australia/New Zealand 
and Northern America, along with Northern and Western Europe due to the widespread 
practice of prostate specific antigen (PSA) testing and subsequent biopsy and 
diagnosis. Asian populations are the ones with the lower incidence rates. Moreover, 
different genetic susceptibility, environmental exposures and access to healthcare 
might also explain this variability among populations. 
 
 
Figure 1 - Incidence and mortality rates of different types of cancer worldwide. Adapted from [7]. 
 
This neoplasia is the fifth cause of cancer-related mortality in men, representing 
6.6% of the total men deaths (Figure 1) [7]. There is less variability in mortality rates 
worldwide than that incidence rates, with a lower number of deaths for PCa in 
industrialized countries. It is not clear whether this is due to earlier diagnosis, improved 
treatment or a combination of these. PSA screening test appears not to be determinant 
for mortality [8]. Mortality rates are high in predominantly black populations, mainly 
Afro-Americans, intermediate in Americas and Oceania and very low in Asia.  
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Figure 2 – Estimated prostate cancer incidence worldwide. Adapted from [7]. 
 
 
 
Risk factors 
The most significant risk factor for PCa is advanced age. Seemingly aging 
exacerbates the molecular, physiological and environmental influences in prostatic 
carcinogenesis.  
 A family history of the disease and African ancestry are also well-established 
risk factors for PCa. Indeed, men with a first-degree relative harboring PCa have more 
than double of risk to develop this disease. Africans have, in fact, the highest 
incidence, mortality and tumor stage and grade at diagnosis, with higher PSA levels as 
they have larger-volume tumors [9]. The reason of these disparities among African men 
is multifactorial: this group has a worse access to diagnosis and treatment due to 
psychosocial, cultural and socioeconomic factors. Moreover it is described that genetic 
factors and the anatomical distribution of the disease contribute to this scenery [9-11]. 
Interestingly TMPRSS2-ERG fusion is less frequently present in African-American men 
than in white men, suggesting a different mechanism of prostate carcinogenesis 
between races [12]. 
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Diagnosis 
Early stage PCa is commonly clinically silent, with no symptoms reported. 
Nevertheless, locally advanced and/or metastatic disease can cause lower urinary tract 
symptoms, hematospermia, and signs of sexual dysfunction [13, 14]. 
Nowadays, the main tools to early detect PCa include the combination of digital 
rectal examination (DRE), serum PSA levels and the diagnosis is generally made by 
transrectal ultrasound (TRUS)-guided biopsy [15]. PSA level is used as a screening 
marker, as the higher the value, the more likely is the existence of PCa, but its use is 
still controversial. PSA is a serine protease produced in prostate that is released into 
the blood after de rupture of normal prostatic structures, which can occur in the context 
of inflammation and urologic manipulation, apart from malignancy of prostate. Along 
with its low sensitivity, PSA testing contributes to overdiagnosis and overtreatment of 
indolent tumors [16].    
European guidelines recommend that men with PSA levels equal or above 4.0 
ng/mL and/or with DRE result that suggests neoplasm are elected to perform a core-
needle prostatic biopsy, in which at least 10-12 cores should be sampled [16].  
Diagnosis of PCa depends on histopathological examination. The majority of 
prostate cancers are adenocarcinomas, yet other types of cancer might appear. 
 
 
Gleason Grading 
The most frequently approach to histopathological grading is Gleason grading 
system, which is the most powerful tool for outcome prediction and for treatment 
selection. This system was developed by Donald Gleason and colleagues and recently 
was updated by the 2014 International Society of Urological Pathology (ISUP) 
Consensus Conference on Gleason Grading of Prostatic Carcinoma [17, 18].     
As most of the tumors have very heterogeneous morphology and typically have 
two or more histologic patterns, a score was created that added the two most common 
grade patterns in a tumor, constituting the Gleason Score (GS), with scores ranging 
from 2 to 10. Gleason grading defines five histological patterns with different levels of 
differentiation, demonstrated by a simple diagram (Figure 3) [18]. It is now 
recommended to use Gleason grading in conjunction with the new grading system 
proposed by the group from Johns Hopkins Hospital (Grade Group 1 = Gleason score 
≤ 6, Grade Group 2 = Gleason score 3 + 4 = 7, Grade Group 3 = Gleason score 4 + 3 = 
7, Grade Group 4 = Gleason score 4 + 4 = 8, Grade Group 5 = Gleason scores 9 and 
10) [19, 20]. 
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Figure 3 – Modified Gleason grading schematic diagram, according to the ISUP. Grade group 1 – Only 
individual discrete well-formed glands; Grade group 2 – Predominantly well-formed glands with lesser 
component of poorly-formed/fused/cribriform glands; Grade group 3 – Predominantly poorly-formed/ 
fused/cribriform glands with lesser component of well-formed glands; Grade group 4 – Only Predominantly 
poorly-formed/ fused/cribriform glands or Predominantly well-formed glands and lesser component lacking 
glands or Predominantly lacking glands and lesser component of well-formed glands; Grade group 5 – 
Lacks gland formation (or with necrosis) with or without poorly-formed/ fused/cribriform glands.  Adapted 
from [18]. 
 
  
  
General Introduction 
6 
 
Clinical and Pathological Staging of Prostate Cancer 
 The most used cancer staging system worldwide is Tumor Node Metastasis 
(TNM) system. This system is based on the size and extension of the primary tumor 
(T), regional lymph nodes involvement (N) and the presence or absence of metastatic 
disease (M). The American Joint Committee on Cancer (AJCC) has defined the rules 
for tumors’ classification based on clinical staging and pathological staging (Table 1) 
[15]. 
 
Table 1 - The 2010 American Joint Committee on Cancer TNM Staging Classification. Adapted from 
[15]. 
Primary Tumor (T) 
Clinical 
Tx         Primary tumor cannot be assessed 
T0         No evidence of primary tumor 
T1        Clinically inapparent tumor neither palpable nor visible by imaging 
   T1a    Tumor incidental histologic finding in 5% or less of tissue resected 
   T1b    Tumor incidental histologic finding in more than 5% of tissue resected 
   T1c    Tumor identified by needle biopsy (e.g., because of elevated PSA) 
T2        Tumor confined within prostate 
   T2a    Tumor involves one-half of one lobe or less 
   T2b    Tumor involves more than one-half of one lobe but not both lobes 
   T2c    Tumor involves both lobes 
T3        Tumor extends through the prostate capsule 
   T3a   Extracapsular extension (unilateral or bilateral) 
   T3b   Tumor invades seminal vesicle(s) 
T4   Tumor is fixed or invades adjacent structures other than seminal vesicles such as external                               
sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
 
Pathologic 
pT2       Organ confined 
   pT2a  Unilateral, one-half of one side or less 
   pT2b  Unilateral, involving more than one-half of side but not both sides 
   pT2c  Bilateral disease 
pT3      Extraprostatic extension 
   pT3a  Extraprostatic extension or microscopic invasion of bladder neck 
   pT3b  Seminal vesicle invasion 
pT4      Invasion of rectum, levator muscles, and /or pelvic wall 
Regional Lymph Nodes (N) 
Clinical 
NX       Regional lymph nodes were not assessed 
N0       No regional lymph node metastasis 
N1       Metastasis in regional lymph node(s) 
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Pathologic 
pNX     Regional nodes not sampled 
pN0     No positive regional nodes 
pN1     Metastases in regional node(s) 
Distant Metastasis 
M0       No distant metastasis 
M1       Distant metastasis 
   M1a  Nonregional lymph node(s) 
   M1b  Bone(s) 
   M1c  Other site(s) with or without bone disease 
 
Primary tumor assessment includes DRE and histologic or cytological 
confirmation of PCa before the first definitive treatment, which establishes the clinical 
staging. In some cases TRUS, magnetic resonance imaging (MRI) and serum PSA 
levels contribute to this staging. Pathological staging, in turn, is determined after radical 
prostatectomy with possible regional lymph node dissection, and allows more 
accurately predict recurrence and prognosis estimation. In addition to pathologic stage, 
independent biological factors have been identified to estimate prognosis. These 
include preoperative serum PSA levels, GS in the prostatectomy sample, comorbid 
illnesses, surgical margin status, seminal vesicles involvement, lymph node metastasis 
and distant metastasis [15].  
 
Therapy 
 Although men with localized disease have a good prognosis and high survival 
rates, when metastases are detected this prospect change [16]. In fact, the prognosis 
of PCa is mainly determined by the presence or absence of metastases and 90% of 
men who die from PCa have metastatic bone lesions [21].  
The PCa therapeutic approach varies according to the extent of the disease, 
and the treatment choice is made based on patient’s age and comorbidities, quality of 
life, TNM classification, GS and preoperative serum PSA level. The current treatment 
options include surgery, radiotherapy, hormone therapy and chemotherapy, yet the 
optimal management of PCa is still controversial among clinicians.  
 
Localized Prostate Cancer 
Localized disease should be classified as low, intermediate or high risk as a 
guide to prognosis and treatment choice. The selection of PCa treatment must take into 
account a balance between the cancer cure and the quality of life. Options for localized 
disease include active surveillance, radical prostatectomy and radiation therapy. 
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 Active Surveillance 
With the widespread increment of the PSA testing, there was a huge increase in 
the number of PCa diagnosed. However it is known that are some low grade cancers 
that are relatively indolent and do not threat patient’s life, what brings the discussion of 
an option for active surveillance (AS) rather than treatment. This surveillance implies 
that men with low-risk PCa (serum PSA <10 ng/mL, GS ≤6 and tumor stage of T2a or 
less), a life expectancy less than 15 years are carefully monitored, until there is 
evidence of disease progression with minimal risk that the cancer will progress from a 
curable to incurable state [16, 22]. Monitoring strategies include DRE and serum PSA 
determinations at 3 to 6 months intervals, with repeated prostate biopsies at intervals of 
1 to 4 years [13].   
Thus, this is a cost-effective option that spares men to the side effects of 
aggressive primary therapy [23]. Still some studies show that this group of men may 
not derive pronounced benefits from active treatment, AS is not yet fully accepted by 
clinicians and patients [24, 25]. 
 
 
 Radical Prostatectomy 
Radical prostatectomy (RP) remains the treatment of choice for cancers 
histologically confined within the prostate gland [16, 26]. Further the possibility of 
having the organ for histological examination allows the confirmation of the 
intraprostatic location of the disease and the surgical margins state. 
RP is recommended for patients with low and intermediate risk localized PCa 
(T1a-T2b, GS 6-7 and PSA ≤20 ng/mL) and a life expectancy above 10 years [16]. The 
need for and the extent of pelvic lymphadenectomy are controversial [27]. The most 
long-term complications after RP are urinary incontinence and erectile dysfunction [13]. 
 
 
 Radiation therapy (External-beam radiation therapy and 
brachytherapy) 
External-beam radiation therapy (EBRT) is a non-invasive therapy effective in 
localized PCa. It is recommended a dose of 74 Gy in low-risk PCa, as it shown to 
increase biochemical disease-free survival [16, 28]. For intermediate-risk PCa, EBRT is 
recommended with dose escalation from 76 to 81 Gy, in combination with 
brachytherapy or short-term androgen deprivation therapy (ADT) [16]. For high-risk 
localized PCa, the recommendations are the combination of EBRT with ADT, for the 
General Introduction 
9 
 
improvement of overall survival [29]. It is also endorsed for patients with a high risk of 
local failure after RP, as adjuvant treatment [16]. The EBRT treatment can be limited to 
the prostate, or extended to the seminal vesicles or lymph nodes [30].  
Brachytherapy consists in the implantation of radioactive seeds within the 
prostate under the ultrasound guidance. This treatment approach has fewer side 
effects when compared with radiation therapy (RT) and is offered to patients that 
present low-grade and low volume disease [31]. 
 
Advanced Disease  
Most patients are diagnosed with low-risk PCa and can be successfully treated 
with surgery or radiation. However, eventually some progress to advanced or 
metastatic disease, with the first sign of recurrent PCa being a rise in PSA, referred as 
biochemical recurrence [32-34]. Additionally, 10-20% of patients already present high-
risk PCa at diagnosis [35]. The European Association of Urology (EAU) definition of 
high-risk PCa includes clinical stage equal or above T3a, PSA equal or above 20 
ng/mL and preoperative GS between 8 and 10 [16]. Although without curative intent, 
the most suitable clinical approach for these patients is androgen deprivation therapy 
(ADT), either by pharmacological or surgical castration (bilateral orchiectomy). ADT 
consists in the effective blockade of the bond of androgenic ligand to androgen 
receptor (AR), either through suppression of androgen production or by agents that 
interfere with ligand-receptor interactions. 
Androgens are required for normal male reproductive system development, 
being the testosterone and dihydrotestosterone (DHT) the main androgens synthesized 
by the testis. When in prostate, testosterone is converted to its more potent form, DHT, 
which binds to AR that, in turn, undergoes translocation to the nucleus where it acts as 
transcription factor [36]. Hence, the androgen suppression in PCa leads to a dramatic 
reduction of prostate cells by apoptosis and cell cycle arrest, resulting in therapeutic 
benefits [37, 38]. 
Commonly, ADT is performed by administration of luteinizing hormone-
releasing hormone (LHRH) agonists or antagonists, eventually combined with anti-
androgens like bicalutamide [39]. ADT might also be used as adjuvant therapy in 
combination with surgical or radiation therapy [40]. Hormonal therapy is also a standard 
of care in metastatic disease, with or without docetaxel [41]. 
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Castration Resistant Prostate Cancer 
 
 Although ADT has a 80-90% initial response rate, the duration of treatment 
varies from 18 to 30 months, followed by a progression of the disease to a lethal state, 
termed castration-resistant prostate cancer (CRPC) [37]. In fact, residual androgens 
that remain after ADT and AR itself are crucial to CRPC progression and growth [37]. 
 The mechanisms responsible for the emergence and evolution of CRPC have 
been extensively studied. Actually two different, but not mutually exclusive, models are 
proposed to explain the onset of this state of the disease, the adaptation and selection 
model (Figure 4) [37]. The adaption model states that tumor cells acquire new genetic 
or epigenetic alterations that enable them to survive in the castrated environment, 
which leads to ADT resistance and tumor relapse. These alterations include 
reactivation of AR signaling by increased levels of intratumoral androgens, AR 
amplification, AR mutations and splice variants, and changes in expression of co-
regulatory molecules [36]. Androgens produced by the adrenal glands 
(androstenedione (AD) and dehydroepiandrosterone (DHEA)) are unaffected by 
conventional ADT, and their concentration are sufficient to activate AR signaling in the 
prostate and maintain PSA expression. Moreover, cancer cells may survive and grow 
under androgen-deprived conditions through androgen-independent activation of AR 
signaling and other bypass pathways [37]. The selection model postulates that 
subclones of prostate cancer cells with varying degrees of androgen dependence are 
already present before hormonal therapy, and the progression to CRPC results from 
the selection and outgrowth of these pre-existing castration-resistant clones in 
androgen depletion conditions [37].  
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Figure 4 – Adaptation versus selection models for CRPC. Adapted from [37]. 
 
 
 As CRPC follows the failure of castration therapy, new therapeutic approaches 
have been developed (Figure 5) [39]. Docetaxel (an antimitotic therapeutic compound) 
chemotherapy represents the first-line treatment for CRPC, but in recent years newer 
agents have been introduced that target some mechanisms of resistance [39, 42]. In 
the United States, Sipuleucel-T was approved for the treatment of asymptomatic or 
minimally symptomatic metastatic CRPC (mCRPC) patients. Next-generation AR 
inhibitors, like enzalutamide, and CYP17A1 inhibitors such as abiraterone are 
approved for CRPC treatment in chemotherapy-naïve and chemotherapy-refractory 
patients. Abiraterone should be considered in CRPC patients with asymptomatic or 
mildly symptomatic metastases and a low metastatic burden due to its survival benefit 
[41]. When resistance to docetaxel is shown, cabazitaxel should be considered as 
effective second line treatment [41].   
Despite the success of second-generation AR-targeted therapies, AR acquired 
resistance mechanisms lead to disease recurrence and ultimately death [36, 39]. It is 
clear that additional therapeutic advances with the potential to overcome resistance 
mechanisms are mandatory, probably evolving towards distinct molecular subclasses 
with individualized therapies, and several clinical trials are ongoing in this direction [36].  
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Figure 5 – Overview of new and emerging therapies for advanced PCa. Adapted from [39]. 
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CANCER STEM CELLS 
 
Definition 
Cancer stem cells (CSCs) are defined as cells with self-renewal and 
differentiation capacity found within tumors. They share those properties and many 
other vital biological phenomena with normal stem cells [43]. Self-renewal is crucial to 
stem cell function so that they can persist throughout lifetime, and a balance must exist 
between this process and differentiation [44]. Cancer might be considered as a disease 
resulting from a disruption of this balance. Thus, contrary to the bulk of cells in the 
tumor, CSCs are biologically unique subpopulation of cells that can perpetuate 
indefinitely, sustaining the malignant growth [45].  
Several mechanisms for tumor phenotypical and behavioral heterogeneity are 
well described, including genetic and epigenetic alterations and interactions with the 
microenvironment [46, 47]. This intratumoral heterogeneity has also been assigned, in 
part, to this malignant sub-population of cells, the CSCs. In fact, CSCs are potentially 
responsible for tumor initiation, progression, metastasis and therapy resistance [44, 
48].  
The clinical relevance of CSCs relies on the discovery that these cells are 
resistant to conventional chemotherapy and to radiotherapy treatment, being one of the 
major causes of treatment failure and subsequent disease recurrence. These oncology 
standard treatments have, in some cases, only a temporary and incomplete effect 
which contributes to tumor burden shrinkage, thus improving patients’ survival.  
However, these effects are frequently transient and patients achieve a therapy resistant 
state. The treatment failure might be due to acquired resistance by the cancer cells or 
to lack of efficiency in killing these CSCs. To overcome this radiation/drug resistance it 
is necessary to target CSCs. 
Remarkably there are several mechanisms of resistance, which are 
summarized in Figure 6 [49]. In this context, it is important to understand and fully 
characterize functional and molecular properties of CSCs, in order to be used as 
therapeutic targets. These properties include a high expression of aldehyde 
dehydrogenase (ALDH), anti-apoptotic proteins and some transporters that act in drug 
efflux (like ABC transporters), the presence of hypoxic niches, increased efficiency of 
DNA repair and alterations in cell cycle kinetics and microenvironmental influences [49, 
50]. CSCs, particularly in leukemias, have a slow cycle nature or are even proliferative 
quiescent. Thus differentiation inducing drugs have been studied in order to stop tumor 
growth and to reduce CSC clonogenicity and tumorigenicity, namely all-trans retinoic 
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acid (ATRA) in acute promyelocytic leukemia [51]. Additionally, they activate pro-
survival signaling pathways as adaptive response to therapy, including Notch, 
Hedgehog (Hh) and Wnt pathways [50]. More, proteins involved in a determined 
pathway were reported to inhibit or activate proteins from other pathways, what might 
potentiate therapeutic resistance [52].  
 
 
Figure 6 – Molecular mechanisms of cancer stem cell resistance to therapy. Adapted from [49]. 
 
 
The evolving cancer models 
It is commonly accepted that the tumor history is determined by the clonal 
evolution of a single progenitor cell that undergoes transformation in the oncogenic 
process (Figure 7B) [53, 54]. Therefore, each cell within a tumor has equal potential to 
acquire alterations, conferring advantages in the tumor development and growth [54].  
In fact, as the tumorigenesis progresses, somatic mutations and epigenetic changes 
accumulates, inducing gene expression deregulation.  
In the 1970s, directly challenging the traditional stochastic model of cancer, 
another evolving cancer model was postulated. It proposes that only a subpopulation of 
cells within a tumor, the CSCs, has the capacity to self-renewal and differentiate, 
sustaining tumorigenesis and driving disease progression, while establishing cellular 
heterogeneity capable of generating similar tumors, in a hierarchical way (Figure 7C) 
[44, 54, 55]. In contrast, progenitor and differentiated cancer cells lose this capacity, so 
that the tumorigenic potential is abrogated [56]. 
The CSC model excludes the tumor heterogeneity as it states that identical 
CSCs drive tumor development and generate identical cellular progenies within the 
tumor [54]. The hierarchical feature of the model could be more transient since it 
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seems that non-CSC, both progenitor and differentiated cells are able to re-acquire 
self-renewal potential (Figure 7D) [54, 57-60]. Additionally, studies in glioblastoma 
shown that non-CSC and terminally differentiated may undergo “dedifferentiation” or 
reprogramming to become CSC, which might continue to self-proliferate and 
differentiate to more transformed neurons and astrocytes. These transformed cells can 
also differentiate in endothelial cells, which again dedifferentiate to CSC [45].  This 
inter-conversion is enhanced through oncogenic transformation [57]. From this point of 
view, the new developing cancer therapies should target not only CSCs but also their 
progeny, as both can generate clones with different chemoresistance levels. 
 
 
 
Figure 7 – The evolving models cancer models. (A) Normal stem cell hierarchy. (B) The clonal evolution 
model. (C) The original CSC model. (D) The fluid CSC model. Adapted from [54]. 
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Evidence for CSC 
There are some controversies regarding the origin of CSC. Stem cells 
themselves may be the target of malignant transformation in certain types of cancer 
[61, 62]. They persist for long periods of time and accumulate alterations that lead to 
self-regulate and cell proliferation loss [44, 63]. In parallel, evidence suggests that the 
cell of origin may be a progenitor cell that is endowed of self-renewal properties of a 
stem cell through genetic and epigenetic modifications, because the progenitor cell 
would otherwise differentiate [44, 64, 65]. This does not mean that the two hypotheses 
are necessarily mutually exclusive, as different subtypes of tumors can behave 
differently.   
Regardless CSC origin, several studies have been shown their existence along 
different tumor types. The first case was reported in acute myeloid leukemia (AML) 
where stem cells could be identified prospectively and purified as CD34+CD38- cells 
from patient samples [61]. These cells were the only ones capable of transferring AML 
from human patients to NOD/SCID mice, confirming that a subset of leukemic cells was 
enriched for the ability to proliferate and transfer disease. 
Some years later, CSCs were also identified within breast cancer [66], as in 
brain, prostate, colon and lung cancer, providing evidence of the CSC model in solid 
tumors [67-70]. Similarly, lineage tracing was used to track progression of tumor 
growth, allowing for the identification of a population of cell with self-renew features in 
several additional tumors, further supporting the CSC model [71-73]. These studies 
also revealed that stemness within CSC is a fluid state dependent on stage of tumor 
development, environment and genetic phenotype. Once again, alterations in tumor 
differentiation lead to different tumor markers expression, what contribute to 
chemoresistance gain.  
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PROSTATE CANCER STEM CELLS 
 
 Prostate cancer stem cells (PCSCs) are a subset of cells within the tumor that 
show tumor-propagating ability and long-term self-renewal potential, which are 
associated with chemotherapy and radiotherapy resistance. The development of 
castration-resistant disease may also be associated with an increased proportion 
and/or activity of PCSCs [74]. Accumulating evidence supports the existence of human 
PCSCs and many characteristics of the PCa indicate that it originates from stem cells.  
 
PCSC Activity 
Current hormonal therapies preferentially reduce the bulk of differentiated AR+ 
prostate cancer cells, whereas AR- CSCs are left behind. CRPC were reported to 
express stem cell genes within the basal layer, suggesting that AR- prostate stem cells 
may contribute to this refractory and advanced state of the disease [75]. ADT may 
promote disease progression to a hormone-refractory state by increasing the PCSC 
castration-resistant compartment and/or activating quiescent CSCs to repopulate the 
tumor with androgen-independent stem cells. 
In addition, ERG (from the androgen-regulated gene fusion TMPRSS2-ERG) 
was found to disrupt AR signaling by inhibiting AR expression, and AR activity, 
whereas induces EZH2 activity (an H3K27 methyltransferase), a polycomb group 
protein that prevents the affected cell from differentiating [76]. These findings provide a 
working model in which TMPRSS2-ERG plays a critical role in maintaining the cell in a 
stemness state. 
Furthermore, other cell signaling pathways were implicating in PCa 
maintenance along with the driving of PCa development, namely PI3K/AKT, 
RAS/MAPK and STAT3. PCSCs seem to utilize these pathways to self-renew within 
the tumor, but the same pathways are also required for PCa cell proliferation, survival, 
tumor angiogenesis and metastasis. High grade PCa has often heterogeneous 
multifocal tumors, which suggests that multiple neoplastic transformations occur within 
the prostate. These dual parts of the cell signaling pathways seems to be relevant in 
heterogeneous PCa that maintain a balanced number of PCSCs within a larger 
population of non-tumorigenic PCa cells [74]. 
Likewise, the progression to CRPC is associated with elevated activity of the 
above mentioned signaling pathways. Indeed, inhibition of AR signaling promotes 
activation of these cell survival pathways, either directly or through cross-talk, in 
surviving androgen-independent PCSCs that drive the development of CRPC [77]. So 
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ADT may not be able to abrogate PCSCs that display activated PI3K/AKT, RAS/MAPK 
or STAT3, in androgen deprivation states (Figure 8) [74]. Preclinical studies have 
already addressed the attempt of blocking these signaling pathways through 
combinatorial strategies towards inhibiting PCa growth [78, 79]. 
 
 
 
Figure 8 – PI3K/AKT, RAS/MAPK and STAT3 signaling pathways in PCSC maintenance and PCa 
tumorigenesis. Adapted from [74]. 
 
 
Cell-of-origin 
The PCa cell-of-origin refers to the cancer-initiating cell(s) within the prostate 
epithelium, whether it is a stem/progenitor cell or its differentiated progeny which 
acquire alterations that prompt the initiating events of tumorigenesis [80]. Considering 
that prostate adenocarcinoma has a luminal phenotype, the cell-of-origin might be a 
luminal cell that suffered neoplastic transformation or a basal cell that had differentiated 
in a luminal progeny during tumorigenesis. In prostate cancer, the origin of the cell that 
suffers transformation is still controversial. 
CSCs are distinct from the cell of origin, as the cell of origin specifically refers to 
the cell type that experiences the first oncogenic hits. Consistently, evidence suggests 
a basal cell-origin for PCa. Within the basal layer, subpopulations of cells have been 
identified with stem cell characteristics which are neither androgen-dependent nor 
androgen-responsive [81, 82]. Basal cells from human primary benign prostate tissue, 
in cooperation with AKT, ERG and AR signaling, can recapitulate the histological and 
molecular features of human PCa upon transplantation, with loss of basal cells and 
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expansion of luminal cells [83]. Murine prostate basal cells have been reported to 
undergo neoplastic transformation, including the capacity for cancer initiation and for 
producing luminal-like disease characteristic of human PCa in multiple models [84]. 
Additionally many of the genes frequently hypermethylated in PCa are found only in 
undifferentiated cells of normal prostate. For example GSTP1, which is 
hypermethylated in more than 90% of PCa cases, was found to be expressed only in 
the basal compartment of normal prostate [85]. 
Although stem-like basal cells are a likely the PCa cell-of-origin, in murine 
models this disease was found to emerge also from luminal cells. Loss of Nkx3.1, 
whose expression is restricted to luminal cells in human prostate, led to the formation 
of pre-neoplastic lesions, with concurrent loss of Pten or overexpression of MYC, 
promoting the development of invasive carcinoma [86, 87]. Murine castration-resistant 
Nkx3.1 expressing cells could self-renew and reconstitute prostate ducts in vivo, and in 
addition to Pten deletion conducted to carcinoma formation following androgen-
mediated regeneration [88]. In a diverse range of mouse models, by genetic lineage-
tracing, luminal cells were consistently found to be the PCa cell-of-origin [89]. Other 
studies suggested that PCa arises from intermediate progenitors that have acquired 
self-renew ability [90]. 
Interestingly, cell-of-origin models propose that distinct cell types within prostate 
cell lineage hierarchy are vulnerable towards tumorigenesis and may give rise to PCa 
subtypes with different histopathology, prognostic and treatment response. 
 
 
Markers 
 The persistence of CSCs in patients after standard treatments led to the 
development of new drugs against this subset of cells. CSC cell surface 
macromolecules or markers constitute potential targets for new therapies. Recently, 
suitable technologies to isolate CSCs from tumors have emerged. Namely monoclonal 
antibodies targeting CSC surface macromolecules, coupled with fluorescent-activated 
cell sorting (FACS), were developed to identify and separate these specific cell 
subpopulations, followed by subsequent transplantation into recipient mice to assess 
their capacity to initiate tumors in vivo [83, 84].  
Nevertheless, stem cells remain poorly characterized due to the absence of 
specific molecular markers that allow for their discrimination from their progeny, which 
have a more restricted proliferative potential. The major limitation relies in the fact that 
no exclusive or even specific stemness markers were defined, thus far. However, the 
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attempts made to identify CSCs are based on normal stem cell markers [61, 66, 67].  
The most exploited surface markers for PCSCs are summarized in Table 2.  
 The first CSC surface marker identified for prostate cancer was CD44, a cell 
surface receptor involved in cell adhesion and migration. Collins et al reported a cancer 
stem cell population from human prostate tumors with significant self-renewal and 
differentiation capacity in phenotypically dissimilar populations of non-clonogenic cells 
(AR+ cells). The authors have used the same stem cell markers that are used to 
designate prostate epithelial stem cells, CD44+/α2β1high/CD133+. This population 
comprised 0.1-0.3% of the total amount of the cells in the tumor [68]. Other report 
found that the CD44+/α2β1high combination phenotype had the greatest tumorigenicity, 
supporting the evidence that this was the CSC population [91]. Later on, a study using 
in vitro sphere-forming assay and in vivo prostate reconstitution assay showed the 
presence of a tumor-initiating subpopulation in a murine prostate PTEN- model, Lin-
/Sca-1+/CD49fhigh. Only this subpopulation was able to initiate a cancerous phenotype 
like the one seen in the primary lesions of the Pten mutant prostate model [92]. 
 Other PCSCs have been discovered via different cell surface markers such as 
CD133, ALDH, CD49f and Trop2 or PSA [83, 93-96]. PSA-/low PCa cells may represent 
a critical source of CRPC cells and can be prospectively enriched using 
ALDH+/CD44+/α2β1+ phenotype [96]. CD44+/CD24- prostate cells were previously 
reported as stem-like cells responsible for tumor initiation and were shown to have 
gene expression patterns that predicts poor patient prognosis [97]. Regarding CD133, 
it is still controversial whether this is a reliable marker for PCSC. Indeed, a study by 
Yamamoto and colleagues showed that this potential stem cell marker was not optimal 
for selection of monolayer and spheroid colony-forming cells (CFCs) both in the benign 
and malignant prostate [98]. 
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Table 2 - Prospective CSC markers for human PCa. 
Stem Cell Markers Model Reference 
CD49f
high
/Trop2
high
 
Basal cells from primary 
benign human prostate 
tissue can initiate PCa in 
immunodeficient mice 
[83] 
CD44
+
/α2β1
high
/CD133
+
 Human prostate tumors [68] 
CD44
+
/α2β1
high
 Human xenograft tumors [91] 
Lin
-
Sca-1
+
CD49f
high
 
Pten prostate cancer 
mouse model 
[92] 
PSA
(-/lo)/
ALDH
+
/CD44
+
/α2β1
+
 Primary tumors [96] 
CD44
+
/CD24
-
 
LNCaP cells form tumors 
in NOD/SCID mice  
[97] 
CD49f
+ 
(CD133 and CD44 are not 
good markers) 
Benign prostate cells and 
advanced prostate cancer 
[98] 
 
 
 Interestingly, all the identified subsets of putative PCSCs lack or have low AR 
expression, which suggests that PCSCs might not be dependent on AR signaling, 
contributing to CRPC development, as previously mentioned. Nevertheless, additional 
studies are clearly needed to evaluate the biological characteristics of PCSCs, and 
their role in CRPC. 
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AIMS OF THE STUDY 
 
 PCa is a heterogeneous disease that ranges from clinical indolent to mCRPC, 
which ultimately culminates in patients’ death. Early-stage disease has good prognosis 
and, in general, patients are effectively treated. However, when PCa reaches an 
advanced or metastatic state, prognosis remains poor and no cure is still available. At 
this stage, patients treated with ADT present tumor shrinkage, but invariably, after 
months or years, tumor acquires resistance to castration conditions, progressing to 
CRPC. Notwithstanding the considerable number of the second-line agents approved 
in the last years, survival is rather limited. Therefore, new therapeutic strategies are 
mandatory to overcome the resistance to androgen axis targeting agents, improving 
management of the disease. 
 CSCs are a subpopulation of cells within a tumor that has been shown to have 
a crucial impact in current failure of cancer therapy because they are responsible for 
tumor formation, progression, metastasis and relapse as well as for therapy resistance. 
Hence, PCSCs may plausibly survive in low-androgen environments resulting from 
ADT, and re-initiate tumor growth upon acquisition of secondary genetic or epigenetic 
alterations, resulting in emergence of CRPC. Hence, PCSCs may be considered as the 
subpopulation responsible for androgen resistance and consequently treatment failure. 
Moreover, a better understanding of the properties and mechanisms underlying PCSCs 
resistance to treatment is necessary to improve patient outcome.   
 Therefore the main objective of this Dissertation was to identify and isolate the 
PCSC population from established cell lines and primary tumors, based on cell surface 
markers expression.  
 Specifically, the aims of this project were: 
 Identify PCSCs subpopulation from PCa cell lines, based on cell surface 
markers expression. 
 Detect and isolate PCSCs subpopulation from PCa cell lines, based on its 
intracellular autofluorescence, by Fluorescence-activated Cell Sorting (FACS). 
 Verify the stemness properties of the subpopulation isolated by 
evaluating the expression of pluripotency-associated genes. 
 
 Identify PCSCs subpopulation from primary tumors, based on cell surface 
markers expression. 
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 Assess the expression of stemness-associated genes in Formalin-fixed, 
Paraffin-embedded (FFPE) prostate tissue samples. 
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MATERIALS AND METHODS 
 
1. Cell Culture 
 In this study, five cell lines derived from human PCa were selected: LNCaP, 
VCaP, 22Rv1, DU145 and PC-3. These PCa cell lines are representative of different 
relevant features of prostatic adenocarcinoma: LNCaP, VCaP and 22Rv1 are hormone-
sensitive cell lines, whilst DU145 and PC-3 are castration-resistant cell lines. DU145 
was obtained from the American Type Culture Collection (ATCC, Lockville, MD, USA), 
whereas LNCaP, VCaP and PC-3 were kindly provided by Prof. Ragnhild A. Lothe from 
the Department of Cancer Prevention at The Institute for Cancer Research, Oslo, 
Norway, and 22Rv1 by Dr. David Sidransky from the Johns Hopkins University School 
of Medicine, Baltimore, MD, USA. 
 All cell lines were cultured in the recommended medium (Table 3), 
supplemented with 10% Fetal Bovine Serum (FBS) (GIBCO, Invitrogen, Carlsbad, CA, 
USA) and 1% Penicillin-Streptomycin (GIBCO). Cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. All PCa cell lines routinely tested for 
Mycoplasma contamination (PCR Mycoplasma Detection Set, Takara Bio, Shiga, 
Japan). 
 
Table 3 - Characteristics of cultured cell lines. 
Cell Line Features  Growth Medium 
LNCaP  Hormone-sensitive  RPMI-1640 
VCaP Hormone-sensitive DMEM 
22Rv1 Hormone-sensitive  RPMI-1640 
DU145 Castration-resistant MEM 
PC-3 
Castration-resistant RPMI-1640 + F-12 Nutrient Mixture 
(Ham) 
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1.1. Riboflavin treatment 
For a better selection of cells with an intrinsic autofluorescent phenotype, the cell 
lines mentioned above were treated with riboflavin before analysis by flow cytometry. 
100.000 cells were seeded in a 6 multi-well plate. After attachment, cells were washed 
with PBS and then were treated with 40 µM Riboflavin (Sigma-Aldrich, Missouri, USA) 
resuspended in the respective culture medium (2 wells were treated with riboflavin and 
2 other wells that did not receive any treatment, whereby they were used as controls).  
After 48 h, it was performed trypsinization; cells were centrifuged at 1200 rpm for 4 
min. The pellet was then ready for flow cytometry analyses.  
 
 
2. Patients and Tumor Sample Collection 
Seven prostate tumor samples from patients with clinically localized PCa diagnosed 
and primarily treated with RP were obtained with written informed consent at the 
Portuguese Oncology Institute – Porto, Portugal. PCa was confirmed by histologic 
examination of representative fragments. For each patient, a tumor sample and a 
respective sample of morphologically normal prostate tissue (NPT) from the peripheral 
region distant from neoplastic lesions were analyzed. Tumors obtained after RP were 
minced with scalpels and resuspended in RPMI medium. 
Tissues were routinely formalin-fixed and paraffin-embedded (FFPE) for standard 
pathologic examination, allowing for tumor classification and WHO/ISUP grading and 
staging. Additionally, FFPE tissue from the same patients was used.  
 
 
3. Flow cytometry and cell sorting 
 
3.1. Flow cytometry 
For flow cytometry, cells were counted, centrifuged at 1800 rpm for 5 min. Cells 
were stained live in FACS Flow (Beckton Dickinson, Heidelberg, Germany), before 
analysis with BD FACS Canto II (BD). 
Primary tumors obtained after RP were mechanically minced with scalpels, 
resuspended in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin. 
The suspension was filtered and centrifuged for 5min at 1800 rpm. The pellet was 
resuspended in FACS Flow. FACS Lysing (BD) was used for the lysis of erythrocytes. 
Samples were analyzed using a FACS Canto II (BD). 
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To characterize cells from both cell lines and tumor samples, the following 
antibodies were used: Anti-Human CD24-Alexa Fluor 647; Anti-Human CD49b-FITC; 
CD49f-PE; EpCAM-PerCP-Cy5.5; CD44-APC-H7 (all from BD). For tumor samples, 
CD45-PO (Invitrogen, Carlsbad, CA, USA) and CD3-APC (Beckman Coulter, EUA) 
were added to exclude hematological cells and T lymphocytes, respectively. Fixable 
Viability Stain (FVS) 450 (BD) was used for exclusion of dead cells. Flow Cytometry 
results were analyzed with Infinicyt. 
 
3.2. Cell sorting 
Firstly, all the five cell lines treated with riboflavin were analyzed for the existence of 
autofluorescence. Cells were washed and resupended in FACS Flow before analysis 
with a BD FACSAria III. DAPI (1:1000) was used to exclude dead cells. Autofluorescent 
cells were excited with a 488 nm blue laser and best selected as the intersection with 
filters 530/40 and 580/30. The gating strategy used for autofluorescence analyses was 
performed as previously described [99]. Results were analyzed using the FlowJo 
Software. 
VCaP, the cell line with more percentage of autofluorescence, and PC-3 were 
selected for cell sorting. As 22Rv1 cell line hasn’t shown any autofluorescence, it was 
selected as negative control in cell sorting. Cells were treated with 40 µM riboflavin 
overnight, before sorting. Autofluorescent cells were excited with a 488 nm blue laser 
and best selected as the intersection with filters 530/40 and 580/30, and a proper 
distance between gates for autofluorescent and non-autofluorescent cells was required 
to achieve high purity during sorting. 
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4. RNA preparation and RT-qPCR  
 
4.1. RNA extraction from cell lines 
Total RNA was extracted from all cell lines pellets’ using TRIzol® Reagent 
(Invitrogen) according to the manufacturer’s manual. Final RNA pellets were eluted in a 
variable volume of RNA Storage Solution (1 mM Sodium Citrate, pH 6.4) (Ambion, 
Applied Biosystems, Foster City, CA, USA) according to pellet size. The eluted RNA 
was then evaluated for concentration and quality using a NanoDrop Lite 
Spectrophotometer (NanoDrop Technologies, USA), and stored at -80 ºC until further 
use. 
 
4.2. RNA extraction from FFPE prostate tissue 
From each case, a representative paraffin block was selected and an experienced 
uropathologist delimited the area of the tumor to be macrodissected. From FFPE 
tissues, 10 µm sections were cut. A disposable sterile scalpel blade was used to 
macrodissect the tumor areas. Tissue samples were then deparaffinized using xylene 
and ethanol 100%, and RNA was extracted with FFPE RNA/DNA Purification Plus Kit 
(Norgen Biotek Corp.,Thorold, ON, Canada), according to manufacturer’s manual. The 
eluted RNA was then evaluated for concentration and quality using a NanoDrop Lite 
Spectrophotometer, and stored at -80 ºC until further use. 
 
4.3. cDNA Synthesis 
1 µg of total RNA from cell lines was reverse transcribed with RevertAid RT Kit 
(Thermo Scientific) using random hexamers, according to manufacturer’s manual. In 
the case of total RNA from FFPE tissue samples, 500 ng were reverse transcribed. All 
samples were stored at -20 ºC. 
 
4.4. Quantitative Real Time PCR 
In order to assess transcript expression levels, quantitative real-time PCR was 
performed in all samples using Fast SYBR Green (NZYTech, Lisbon, Portugal). 
cDNA was used as template and submitted to reactions with the target genes (the 
list of primers used and their respective qPCR conditions can be found in 
Supplementary Table I). All expression assays were performed using LightCycler 
480 II (Roche, Germany) as per the manufacturer’s instructions. 
The GUSB assay was used to normalize cDNA input. All samples were run in 
triplicate and two negative controls were included in each plate. The standard curve 
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method was used for quantitation as well as ascertaining PCR efficiency. Universal 
Human Reference RNA (Stratagene, Santa Clara, USA) was used to prepare five 
consecutive dilutions by a 5x dilution factor. All plates had an efficiency between 
90-100%. The expression values were determined as: mean quantity of the gene of 
interest expression/mean quantity of GUSβ. Then, the values were multiplied by 
1000 for easier tabulation. 
 
5. Statistical analysis 
Multiple and pairwise comparisons were performed using the Kruskal-Wallis and 
Mann-Whitney U tests, accordingly, both in clinical samples and in in vitro experiments. 
Spearman correlation tested association between transcript levels of different 
genes. Statistical significance was set at p < 0.05. Results are presented as mean ± 
s.d. Analyses were performed using GraphPad Prism 6. 
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RESULTS 
 
1. Identification of PCSCs in PCa cell lines, using Flow Cytometry 
 
The combination of cell surface markers for PCSCs identification was chosen 
according with the published literature and is listed on Table 4. Thus, the phenotype 
EpCAM+/CD24-/α2β1
high/CD49f+/CD44+ was selected for PCSCs identification. 
 
Table 4 – Cell surface markers for PCSCs identification in PCa cell lines.  
Cell Surface Marker Conjugated fluorochrome Clone 
EpCAM 
+ 
PerCP-Cy 5.5 EBA-1 
CD24 
- 
Alexa Fluor 647 ML5 
α2β1 (CD4b) 
high 
FITC AK-7 
CD49f 
+ 
PE GoH3 
CD44 
+ 
APC-H7 G44-26 
 
To establish whether PCa cell cultures contained PCSCs, multivariable gated 
flow cytometry was used and the proportion of PCa cells expressing EpCAM+/CD24-
/α2β1
high/CD49f+/CD44+ stem cell markers alone and in combination was evaluated 
(Supplementary Figure I; Table 5). Positive expression was considered above 10-3 and 
it was always compared with the negative control (unstained cells). Firstly, only living 
cells were selected, by gating negative expression for the viability dye (FVS) 
(Supplementary Figure Ia). All cell lines showed EpCAM expression, confirming their 
epithelial phenotype (Supplementary Figure Ib).  Contrarily to expected, all PCa cell 
lines presented a homogeneous expression of all the studied markers, and therefore, 
no specific populations could be identified. The expression pattern is displayed in Table 
5. Specifying, DU145 and PC-3 were positive for all the stem cell markers (CD24, α2β1, 
CD49f and CD44). However, EpCAM stained heterogeneously in DU145 cells. VCaP 
presented positive CD24, CD49f, and α2β1 expression, whilst CD44 was very 
heterogeneous. Additionally, LNCaP was positive for CD49f, and α2β1 and CD24 
negative, with a rather heterogeneous CD44 expression, scattered in three different 
subpopulations. 22Rv1 showed a rather dissimilar expression pattern compared with 
the other PCa cell lines. Indeed, no expression was found for CD24, neither CD49f nor 
α2β1 in these cells (Supplementary Figure I).  
 
  
Results 
30 
 
Table 5 – PCa cell lines expression of stem cell markers, by flow cytometry. 
Cell Line EpCAM CD24 
α2β1 
(CD49b) 
CD49f CD44 
 
LNCaP
 
+ - - + 
Heterogeneous 
(3 populations) 
 
22Rv1
 
+ - - - Heterogeneous  
VCaP
 
+/- + + + Heterogeneous  
DU145
 
Heterogeneous ++ + + +  
PC-3 + + + ++ ++  
(+) – positive expression; (++) – high expression; (+/-) – low expression (-) – negative expression. 
 
To identify the population of interest, the first strategy adopted was gating the 
living cells population (dead cells are represented in red) and then gating CD24- cells 
(Supplementary Figure Ic), since it is described that CSCs are CD24 negative [97]. 
From the CD24- population, cells that co-expressed the remaining markers (EpCAM, 
α2β1, CD49f, CD44) were selected to enrich the putative PCSC subpopulation. In 
LNCaP and VCaP cell lines, the CD24- population was CD49f positive, but α2β1 
negative. However, because CD24+ population was not clearly separated from CD24- it 
was not possible to isolate a population. 
DU145 and PC-3 cell lines were rather homogeneous, both of them expressed 
CD24 overall. Therefore, this strategy is not useful to discriminate sub-sets of 
populations in these cells. Conversely, 22Rv1 was CD24 negative, but also did not 
express α2β1 and CD49f, as previously mentioned, hindering populations 
discrimination. 
Therefore, the selected stem cell markers were unable to identify a population 
of PCSCs in any of the studied PCa cell lines. 
. 
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1.1. CD44 and α2β1 expression correlates with PCa cells malignant 
features  
 
CD44 is a cell-surface glycoprotein involved in cell adhesion and migration. CD44+ 
PCa cells were previously described to be inherently more tumorigenic and metastatic 
than the isogenic CD44- PCa cells. Moreover, CD44+ cells were reported to have tumor 
progenitor’s intrinsic features [100]. Similarly, α2β1, an integrin expressed in the human 
prostate that mediates adhesion to collagen I/IV and laminin I, has been also proposed 
to identify human prostate stem cells [91]. Here, to determine whether CD44 and α2β1 
were expressed in more tumorigenic PCa cells, their expression were examined using 
flow cytometry analysis, as previously shown. 
DU145 cells, which display intermediate malignancy characteristics [101], showed a 
strong expression of CD44. The most representative of tumorigenic and metastatic AR- 
PCa cells, PC-3, presented the highest CD44 expression levels (Figure 9). In contrast, 
AR+ low-tumorigenic, non-metastatic PCa cells lines [101], LNCaP and 22Rv1, 
displayed a very heterogeneous CD44 expression pattern, without a clear positive 
CD44 population of cells (Figure 9).  
 
 
Figure 9 – Representative flow cytometry analysis for CD44 expression in PCa cell lines. DU145 and PC-3 
depicted a strong CD44 expression, which might be related with increased tumorigenic and metastatic 
phenotype. 
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Regarding α2β1 (CD49b), AR
- PCa cell types, DU145 and PC-3, revealed high α2β1 
expression levels, whereas LNCaP and 22Rv1 cells did not show any detectable α2β1 
expression (Figure 10).  
 
 
 
 
Figure 10 – Representative flow cytometry analysis for α2β1 expression in PCa cell lines. DU145 and PC-
3, the more malignant cell lines displayed a strong α2β1 expression.  
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1.2. Comparison between flow cytometry data and stem cell markers’ 
transcript levels 
 
Transcript expression levels of the markers evaluated by flow cytometry were 
assessed by RT-qPCR analysis. Additionally, SOX2 and POU5F1 (two other stem cell 
markers) expression levels were also analyzed. 
Actually, α2β1, CD49f and CD24 membrane expression correlated with transcript 
expression leveIs (Figure 11; Table 5).  
Overall, AR- cell lines (DU145 and PC-3) along with VCaP, exhibited the highest 
α2β1 (CD49b), CD49f, CD44 and CD24 expression levels (Figure 11). Although SOX2 
and POU5F1 were expressed in the PCa cell lines, levels are rather low, particularly 
those of SOX2. PC-3 cells presented the highest expression levels for these markers 
(Figure 11). 
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Figure 11 – RT-qPCR analysis of the stemness markers. (A) Markers used to isolate PCSCs (α2β1, 
CD49f, CD44 and CD24), in PCa cell lines. AR expression was also analyzed. (B) Pluripotency-associated 
genes, SOX2 and POU5F1, expression analysis. Each was performed in triplicate. Data shown were 
normalized for GUSβ expression. Error bars, s.d. 
 
 
As observed in Figure 9 and 11, AR- cell lines (DU145 and PC-3) have a 
significant higher expression of CD44. In fact, AR and CD44 expression levels were 
inversely correlated (r = -0.76, p < 0.0001), whereas α2β1 (CD49b) and CD49f 
expression strongly correlated (r = 0.80, p < 0.0001) (Table 6). Actually, the same 
expression pattern was observed for the latter transcripts in all the analyzed cell lines 
(Figure 11A). 
 
 
Table 6 – Correlations between transcript levels of the tested genes in PCa cell lines.  
Genes r p 
CD44 vs AR -0.76 < 0.0001 
α2β1 vs CD49f 0.80 < 0.0001 
POU5F1 vs AR
 
0.53 < 0.0001 
Correlations were assessed by Spearman’s correlation test.    
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2. PCSCs identification by intrinsic autofluorescence 
 
Because it was recently reported that intrinsic autofluorescent phenotype may 
identify and characterize a distinct population of self-renewing and highly tumorigenic 
CSCs [99], we tested that approach in collaboration with colleagues from ICVS. 
Autofluorescence is due to the ability to concentrate riboflavin in ABCG2-coated 
intracellular vesicles.  
 
 
2.1. Detection of intracellular autofluorescence in PCa cell lines 
 
Since riboflavin enhances the ability to isolate autofluorescent cells from cell lines, 
in which autofluorescence was difficult to detect with regular riboflavin concentrations 
(0.5 µM), each PCa cell line was treated with 40 µM riboflavin. Cells without riboflavin 
treatment were used as negative controls.  
VCaP showed the highest percentage of autofluorescent cells (2.03%), being the 
most promising for PCSCs isolation (Figure 12), following by PC-3 that displayed 
1.02% of autofluorescent cells (Figure 12). Although DU145 and LNCaP presented 
1.51% and 1.5% of autofluorescence levels, respectively, their intensity was lower, 
which is due to the riboflavin attachment to the exterior of the cell (Figure 12). 22Rv1 
cell line did not display intrinsic autofluorescence, and was used, therefore, as a 
negative control.  
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Figure 12 – Flow cytometry analysis of autofluorescent content in PCa cell lines. Autofluorescent cells are 
excited with a 488-nm blue laser and best selected as the intersection with filters 530/40 and 580/30. 
VCaP presented the highest level of autofluorescence (2.03%). PC-3 (1.02%) also exhibited some 
autofluorescence. DU145 (1.51%) and LNCaP (1.75%) showed a performance with very little 
autofluorescence intensity, and 22Rv1 did not show autofluorescence. Control – cells not treated with 
riboflavin. RBV – cells treated with 40 µM riboflavin. 
 
 
2.2. Autofluorescent cells from sorting 
 
 As VCaP cell line showed the highest intrinsic autofluorescence, positive (Fluo+) 
and negative (Fluo-) cells for this phenotype were separated by FACS, to verify 
whether this characteristic was associated with stemness features, namely 
pluripotency-associated expression genes. Similarly, PC-3 cells were also separated 
and evaluated for the presence of these properties, whereas no Fluo+ cells were 
possible to isolate from 22Rv1 cells. 
Unexpectedly, Fluo+ cells did not significantly overexpress pluripotency-associated 
genes (Figure 13). In fact, Fluo+ cells displayed significantly lower levels of these 
genes than Fluo- cells. The only exception was PC-3 Fluo+ cells in which a significantly 
higher POU5F1 expression was observed (p < 0.05). 
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Figure 13 – RT-qPCR analysis of the markers used to isolate PCSCs (α2β1, CD49f, CD44, CD24), in 
sorted Fluo- and Fluo+ cells from VCaP and PC-3 PCa cell lines. AR and the pluripotency-associated 
genes, SOX2 and POU5F1, were also evaluated. Data shown were normalized for GUSβ expression. 
Error bars, s.d. 
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3. PCSCs identification in primary tumors, using Flow Cytometry 
 
To verify whether CD49f+/α2β1
high/CD44+ cells were present in primary prostate 
tumors, multivariable gated flow cytometry was used to determine the proportion of 
α2β1/CD49f/CD44-expressing cells in seven prostate tumors (Supplementary Table II). 
Because CD3 antibody (used to exclude T lymphocytes) was conjugated with APC 
fluorochrome, CD24 (conjugated with AlexaFluor 647) was excluded, as they had 
overlapping emission spectrums. The percentages of each population are summarized 
in Table 7. CD44 was the surface marker significantly most expressed in the majority of 
the samples, whereas CD49f, and mainly α2β1, showed low expression in all the 
samples analyzed. Intriguingly, no differences were apparent for α2β1/CD49f/CD44 
expression between NPT and the paired tumor sample. 
For each case, the population of leukocytes was clearly identified by a gate in 
CD45 histogram and, within this population, about 95% were CD3+, this is, T 
lymphocytes (represented in pink) (Supplementary Figure IIB a, b). Neutrophils and 
monocytes were also present in some samples and were identified in CD45 
histogram/dotplot. 
Due to cell aggregation, tumor and NPT samples were difficult to acquire in the 
cytometer (Supplementary Figure IIA). Moreover, along with cell death, exuberant 
pleomorphism was seen in all the samples. In fact, alteration of morphological features’ 
was notorious, and may have influenced the staining.       
Since T lymphocytes were easily identified, we attempted to establish a cut-off 
based on T lymphocytes positivity/negativity for the markers. However, the remaining 
populations of cells were difficult to identify and isolate, as they showed an abundant 
autofluorescence that culminated in unspecific staining. Moreover, a population of large 
size and complex cells, resembling autofluorescence due to unspecific staining, was 
present in all samples (Supplementary Figure IIB, c). This population also strongly 
expressed CD45, suggesting the existence of unspecific staining, and was considered 
as debris.  
Automatic Population Separator (APS) is a tool of Infinicyt software that 
automatically separates out cell clusters based on immunophenotype, taking into 
account all parameters for the best separation possible. This tool allowed the isolation 
of a population that was CD3-/EpCAM+/α2β1
+/low/CD49f+/CD44+ (Supplementary Figure 
IIB, h, represented in blue). The percentage of this population ranged from 0.05-0.32% 
in NPT, and from 0.10-2.05% in tumors. In fact, in the majority of analyzed samples this 
hypothetic stem cell population was larger in tumors than in NPT, regardless of GS and 
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TNM staging. Nevertheless, this putative population might not be further considered 
due to its elevated levels of autofluorescence, which can influence the surface markers 
real expression (Supplementary Figure IIB, h). 
 
Table 7 – Characterization of the populations in primary tumors samples, by flow cytometry.  
Patient no. T Lymphocytes α2β1
 
CD49f
 
CD44 
Possible population of interest 
(CD3
-
/EpCAM
+
/α2β1
+/low
/CD49f
+
/CD44
+
) 
P1 NPT 
P1 T
 
4.29% 
5.47% 
0.47% 
4.21% 
1.26% 
2.91% 
82.60% 
76.15% 
0.07% 
0.11% 
P2 NPT 
P2 T 
2.37% 
2.38% 
0.16% 
0.52% 
4.75% 
4.43% 
82.94% 
79.11% 
0.19% 
0% 
P3 NPT 
P3 T 
2.87% 
7.5% 
0.56% 
0.83% 
10.21% 
2.18% 
60.11% 
77.14% 
0.32% 
0.94% 
P4 NPT 
P4 T
 
3.09% 
2.95% 
0.58% 
0.26% 
2.64% 
5.05% 
86.47% 
43% 
0.06% 
0.10% 
P5 NPT 
P5 T 
2.66% 
4.49% 
5.27% 
2.69% 
3.35% 
9.50% 
70.83% 
68.85% 
0.05% 
0.30% 
P6 NPT 
P6 T
 
0.69% 
4.00% 
0.39% 
0.21% 
6.93% 
3.58% 
83.90% 
83.93% 
0.14% 
2.05% 
P7 NPT 
P7 T 
5.43% 
3.50% 
0.72% 
0.19% 
6.03% 
2.17% 
82.45% 
90.17% 
0.25% 
0.14% 
NPT – Normal prostate tissue (adjacent to tumor); T – Tumor. P1-P4 represent patients with GS=7; 
P5-7 represent patients with GS > 7. 
 
 
3.1. Expression of stemness-associated genes in primary tumors, 
from FFPE prostate tissue samples 
 
Subsequently, the same stemness-associated markers evaluated by flow cytometry 
were assessed by transcript levels in PCa tissues from the respective FFPE sample 
(α2β1, CD49f and CD44), along with CD24, AR, POU5F1 and SOX2. 
The results were not uniform along samples, neither between NPT and tumor 
tissue. Generally, the analyzed genes were significantly (p <0.05) more expressed in 
NPT than in tumor samples (Figure 14). CD44 seemed to display higher expression in 
tumors with lower GS (GS=7; Figure 15; Table 8). Interestingly, case P6 showed 
significantly higher expression of all the analyzed transcripts in NPT. In contrast, case 
P2 exhibited a higher expression of the referred markers in tumors (Table 8).  
PCa samples (both NPT and tumor) did not show SOX2 expression. Additionally, 
α2β1 strongly correlated with CD49f expression (r = 0.75; p < 0.0001; Table 8). AR and 
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POU5F1 exhibited the same expression patterns (Table 8), although their correlation 
was not so strong (r = 0.38; p < 0.05). 
 
 
 
 
 
Figure 14 – Representative qPCR analysis of the markers used to isolate PCSCs (α2β1, CD49f, CD44), in 
NPT and the respective tumor samples from FFPE prostate samples. CD24, AR and the pluripotency-
associated genes, SOX2 and POU5F1, were also evaluated. Each was performed in triplicate. Data shown 
are normalized for GUSβ expression. Error bars, s.d. Statistical significance was assessed by Mann-
Whitney test, * p < 0.05, ** p < 0.01. 
 
 
Table 8 – Genes expression levels’ in RP tumor samples relatively to NPT. Correlation was assessed by 
Spearman Correlation’s test, * p < 0.05, **** p < 0.0001 
Cell Line CD44 α2β1 (CD49b) CD49f CD24 AR POU5F1 
P1 + - - - - - 
P2
 
+ + + + + + 
P3 + - - + =/- - 
P4 -/= - - - - - 
P5
 
+ - - = - - 
P6 - - - - - - 
P7 - - - + + + 
Correlation r = 0.75 ****  r = 0.38 * 
(+) - increase of gene expression in tumor samples relatively to NPT. (-) - decrease of gene expression in 
tumor samples relatively to NPT. (=) - equal gene expression in both tumor and NPT samples. 
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Figure 15 – Representative qPCR analysis of the stem cell markers used to isolate PCSCs (α2β1, CD49f, 
CD44), in tumors from FFPE prostate samples. CD24, AR and the pluripotency-associated genes, SOX2 
and POU5F1, were also evaluated. Each was performed in triplicate. Data shown were normalized for 
GUSβ expression. Error bars, s.d. P1-P4 represent patients with GS=7; P5-7 represent patients with GS > 
7. 
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DISCUSSION 
 
The CSC model claims that a small subset of cells within the tumor act as a 
reservoir of self-sustaining cells with the tremendous ability to self-renew and sustain 
the tumor. This subset represents the quiescent and highly tumorigenic CSCs, which 
are at the top of the hierarchical organization of the tumor and give rise to other 
subpopulations of progenitor cells. These cells in turn, will develop into a spectrum of 
cells at different stages of differentiation [102]. This organization helps to explain how 
the remarkable heterogeneity that characterizes PCa can be generated. In fact, PCSC 
may be the cause of treatment failure in advanced disease, in which invariably all 
patients relapse. Accordingly, several studies provided evidence for a hierarchical 
organization of prostate cancer cells and this has prompted for the finding of markers 
that could select these tumor-initiating cells or CSCs. Numerous strategies have been 
employed to isolate this subpopulation, but no consensus has been reached, and 
doubts arise about which population is really selected. In line with those attempts, we 
assessed the presence of CSCs in PCa cell lines and primary tumors, using a 
combined marker strategy (EpCAM+/CD24-/α2β1
high/CD49f+/CD44+) to enrich for 
tumorigenic PCSCs. We found that with that combination of markers a distinct PCSC 
subpopulation could not be identified. Unfortunately, within the same cell line, all cells 
displayed the same staining pattern (Supplementary Figure I). Contrarily to our results, 
a previous study identified a subpopulation of CD44+CD24- in LNCaP and DU145 that 
displayed stem cell characteristics [97]. Nevertheless, in our set of samples, we did not 
observe the same staining results. Li and colleagues have also identified tumor cell 
holoclones with stem-like cells, in PC-3 and DU145, which could initiate serially 
transplantable tumors and express high levels of CD44, α2β1 and β-catenin [103]. In 
primary tumors, a population of CD44+/α2β1high/CD133+ was also identified as CSC 
phenotype [68]. These studies suggested CD44 as marker of great potential; but it is 
not clear which is its best counterpart combination. Thus, further testing of alternative 
surface markers that might identify a subpopulation of PCSCs is required. 
Nevertheless, in PCa cell lines, a general increase in expression of α2β1 and 
CD44 in the more tumorigenic, CRPC and metastatic cell lines (DU145 and PC-3) [101] 
was observed, as well as in the androgen-responsive cell line VCaP (Table 5; Figure 9, 
10). This has been previously reported by Patrawala and colleagues regarding CD44 
and α2β1 [91, 100], suggesting that the abundance of these markers in PCa cell 
cultures is correlated with cell tumorigenicity and hormone-sensitive status. In fact, 
LNCaP cells, which are the least aggressive [101], did not show detectable expression 
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of α2β1 and presented minimal expression of CD44, either by flow cytometry or RT-
qPCR.  
Moreover, AR and CD44 were shown to be inversely correlated (r = -0.76, p < 
0.0001), confirming that CD44+ cells might have a strong tumorigenic and metastatic 
potential, as previously reported. Indeed, since AR is the relevant target of ADT, 
determining its expression in PCSCs is of dominant importance. Several studies 
suggest that primary and untreated tumors display CD44+/AR- PCSCs, which are 
androgen-responsive and able to differentiate in AR+ cells [102, 104]. The putative AR- 
PCSC is likely to form a core after ADT, contributing to the evolution of CRPC [105]. 
SOX2 and POU5F1 were also evaluated at mRNA level as they represent 
pluripotency-associated genes and it would be expected that cell lines with higher 
percentage of PCSCs had, to some extent, increased expression of these markers. 
Actually, PC-3 revealed a significantly higher expression of those genes, disclosing 
again some association between PCa aggressiveness and pluripotency-associated 
genes expression. 
 Although surface markers such as CD133 and CD44 have been successfully 
used to isolate PCSC, their expression levels vary considerably on the basis of 
environmental changes, which could result in variable enrichment for CSCs. Their 
expression is neither exclusively linked to a CSC phenotype. In an attempt to overcome 
this problem, a study has identified a distinct subpopulation of cells with an inherent 
intracellular autofluorescent phenotype, which exclusively showed CSC features, 
including in vivo tumorigenicity [99]. This autofluorescence was related to the CSCs’ 
ability to concentrate the fluorescent vitamin riboflavin in ATP-dependent ABCG2-
coated intracellular vesicles. This feature allowed for the identification and isolation of a 
CSC population from the bulk of the tumors xenografts and primary tumors that could 
be excited with a standard blue laser, using flow cytometry and purified by FACS [99]. 
In the present study, we applied the same strategy to identify this CSC subpopulation 
in PCa cell lines. This property was mainly observed in VCaP cell line, suggesting that 
it may have the largest proportion of PCSCs. However, when the studied markers and 
pluripotency-associated genes expression were evaluated, it was not possible to 
distinguish between Flou+ and Flou- (Figure 13). Still, VCaP showed considerable 
expression of CD49f, CD44, SOX2 and POU5F1, that was even superior to that of 
DU145, which is a more tumorigenic cell line [101]. On the other hand, and although 
PC-3 cells did not disclose the highest autofluorescence, PC-3 Fluo+ cells revealed a 
significantly higher expression of POU5F1 than PC-3 Fluo- cells (Figure 13). In fact, 
these results are in line with those obtained by flow cytometry. PC-3 is the most 
malignant and metastatic cell line and it expressed higher levels of α2β1 and CD49f, as 
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well as of SOX2 and POU5F1, which might suggest a more stemness/progenitor 
phenotype. 
Therefore, and contrarily to what was described for other tumor models, this 
technique was not able to discriminate PCSCs from the bulk of PCa cells. 
Nevertheless, it is important to underline that the results found by Miranda-Lorenzo and 
colleagues [99] were essentially derived from pancreatic xenografts, which are much 
more aggressive that PCa and it might harbor a larger population of CSCs.    
 Another strategy for PCSCs identification might be the side population (SP) 
technique, which is an assay that relies on the ability of stem-like cells to preferentially 
express drug-efflux pumps such as ABCG2 instead of putative CSC markers. However, 
this technique seemed also to have failed detection of a reliable SP in PCa [106]. 
 After testing PCa cell lines, we searched for putative PCSCs in primary tumors 
obtained from RP specimens. In addition to the difficulties in acquiring these samples in 
the cytometer (Supplementary Figure IIA), the samples were characterized by a 
pronounced pleomorphism and intense cell death. The morphological alterations 
observed in cells might have influenced staining. In all NPT and tumor samples, cells 
have shown high autofluorescence levels, which is a typical pattern and this had 
hampered a good analysis. Additionally, it was not possible to distinguish NPT and 
tumor samples, by flow cytometry. 
 There are a number of technical aspects regarding sample processing which 
must be carefully evaluated. In this study, samples were preserved in culture media to 
avoid tissue degradation and antigen alteration. However, some clump formation, cell 
death and non-specific binding of fluorochrome-conjugated antibodies were 
unavoidable. The most critical step is enzymatic digestion, as the collagenase 
treatment may lead to an alteration in expression of cell-surface molecules. 
Alternatively, samples were mechanically processed only, although this procedure 
might be followed by centrifugation on Ficoll layer. Furthermore, cell surface markers 
determination alone are of limited value for unequivocal identification of CSC, 
especially in tumor tissues [107]. Thus, it might be more advantageous to use several 
markers and properties in combination, like SP or ALDH analysis.   
 Nevertheless, we may assure that the technique was faultlessly performed as 
the leukocyte population, including T lymphocytes, neutrophils and monocytes, were 
clearly identified and isolated. The problem lies in the identification of the subpopulation 
of interest (EpCAM+/α2β1
high/CD49f+/CD44+), that was only identified by the APS tool of 
the software of analysis. In the majority of the cases, the hypothetic subpopulation was 
shown to be larger in the tumor compared to NPT regardless of GS and stage. Even 
so, this putative population seems to result from the intrinsic autofluorescence of the 
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sample, as it revealed high staining for CD45, in the same intensity of the debris 
(Supplementary Figure IIB, h). Another problem is that this population could not be 
sorted, as the sorter equipment does not have the APS tool. Thus, no further studies 
are possible in order to evaluate the stemness properties of the aforementioned 
subpopulation.  
 When gene transcripts of NPT and tumor samples were analyzed, it was found 
that α2β1, CD49f, CD44 and AR were significantly more expressed in NPT than in 
paired tumor samples, regardless of GS and stage. These findings, partially, support 
the hypothesis that molecules expressed by normal stem cells might serve as markers 
of CSCs. On the other hand, it has to be taken into account that tumors derived from 
different patients, and even different tumor foci in the same patient, present several 
variations in their genetic and phenotypic alterations, as PCa is characterized by 
considerable heterogeneity. This interferes with the comparison of tumorigenic 
populations between different patients and even worst with the NPT (adjacent to 
tumor). NPT regions could themselves possess as many as ten genetic mutations 
[108], highlighting the difficulties in comparing normal and tumor tissues that were 
clearly present in flow cytometry analysis. 
In addition, CD44 expression has been found more frequently in NPT and in 
high grade prostatic intraepithelial neoplasia (HGPIN) [109], and seems to have a 
higher expression in tumors with lower GS (Figure 15). Loss of expression of CD44 has 
already been correlated with increased Gleason grade [110]. However, our number of 
samples was very limited, precluding definitive conclusions. Oct4 (the protein encoded 
by the POU5F1) nuclear expression was reported to be strongly associated with NPT 
and HGPIN but not PCa [109]. This is, however, controversial, since other study 
showed POU5F1 expression in tumors but not in normal somatic tissues [111]. 
However, at mRNA level, no differences were found in our study. SOX2 could not be 
detected in our samples, probably because the proportion of cells that express this 
gene is very low and the distribution of the cell types differ in distinct parts of the tumor. 
The main observation in tumor samples is the strong correlation observed between 
α2β1 and CD49f staining, and the same trend for AR and POU5F1 staining (Table 8). 
 Therefore, the selected surface markers have not allowed for the identification 
and isolation of a population of PCSCs, either in PCa cell cultures or in primary tumors.  
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CONCLUSION AND FUTURE PERSPECTIVES 
 
 Although PCa is one of the most common malignancies diagnosed in men 
worldwide, the knowledge of prostate tumorigenesis, including its origin and 
progression, remains limited. In addition to specific genetic and epigenetic alterations 
that accumulate over time, nowadays PCSCs are believed to represent the driving 
force of prostate tumorigenesis and several efforts have been made to isolate and 
characterize them adequately. PCSCs may be dynamic units which are likely to display 
variable phenotypes, produce different PCa subtypes and promote the development of 
CRPC. In the present work, we attempt to isolate a subpopulation of PCSCs based on 
the expression of the surface markers EpCAM+/CD24-/α2β1
high/CD49f+/CD44+, using 
flow cytometry. Unfortunately, the selected markers did not allow or were insufficient for 
the identification and isolation of this subpopulation, in either PCa cell lines or primary 
tumors. As the combination of cell surface markers is not well established, yet, another 
approach was performed in which the intracellular autofluorescence phenotype of PCa 
cell lines was analyzed. Despite two PCa cell lines, VCaP and PC-3, revealed 
promising results in terms of the presence of PCSCs by autofluorescence, it was not 
possible to discriminate between positive and negative cells for this phenotype in the 
evaluation of gene transcripts. Sorting experiments to perform evaluation of 
pluripotency-associated genes’ expression are ongoing. The intracellular-
autofluorescent positive cells will be further assessed for the ability to form prostate 
spheres. Sphere formation has long been used to enrich and select for CSCs. If 
possible, the putative PCSC population will be assessed for its tumorigenicity, by their 
ability to initiate tumor development in NOD/SCID mice, which is the “gold standard” for 
CSCs confirmation. 
Meanwhile, other mesenchymal and quiescent cell markers will be tested, in 
order to identify the population of interest. Several reports indicate that CD44+ prostate 
cancer cell population is heterogeneous, with approximately 1% of the CD44+ cells 
representing CSCs. CD44 seems to be a great potential marker for PCSCs 
identification, but it is still unclear which is its best counterpart combination to enrich for 
the most characteristic stem cell population.   
 As T lymphocytes were clearly isolated in primary tumor samples, and since 
immunotherapy has recently emerged in Oncology, it will be of further interest to study 
this population of cells, in particular, the intratumoral immune-modulation of the T 
lymphocytes. In fact, current anti-PCa hormonal therapies preferentially target the bulk 
of differentiated cells without targeting AR independent compartments, which might 
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explain why patients initially respond to therapy but end up recurring. Available 
chemotherapy regimens target the high proliferative cells leaving the slow-cycling 
PCSCs unaffected, which may explain its lack of effectiveness. The development of 
novel therapeutics that targets the stemness of PCSCs, which might be used in 
conjunction with ADT, is mandatory to prevent tumor recurrence and progression.     
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Supplementary Figure I – Representative flow cytometry analysis for the indicated markers in PCa cell 
lines. (a) Death cells were excluded by gating FVS450 positive cells. (b) EpCAM expression. (c) CD24
-
 
cells (green) were gated, in order to evaluate the coexpression of the other markers. CD24
+
 cells are 
represented in blue. (d-f) Histograms representing α2β1, CD49f and CD44 expression, respectively. In 
VCaP, no viability dye was available; for that reason, death cells were gated based on FSC/SSC and in 
APS. 
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Supplementary Figure II – Representative flow cytometry analysis for the indicated markers in prostate 
tissue samples from radical prostatectomy. Plots shown are representative of the tumor (right panel) and 
the respective NPT (left panel) from the peripheral region distant from neoplastic legions. (a) Leukocytes 
were gated (yellow) based on CD45 staining, as they have formed a clear population. (b) Between this 
population, the majority were T lymphocytes, as they express CD3 (pink). (c) FSC-A and SSC-A dotplot 
allowed for the identification of autofluorescence, representing unspecific staining (orange). (d-g) 
Representative histograms of α2β1, CD49f, EpCAM and CD44 expression, respectively. (h) CD45 
representative histogram showing that autofluorescence gated cells and the putative population isolated 
based in APS and the surface markers (blue) have an intense positive staining for CD45; this corroborates 
the hypothesis that this might represent unspecific staining.  
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Supplementary Table I – Primers sequences used and qRT-PCR conditions.  
Gene Forward (F) Reverse (R) 
Annealing 
(TºC) 
Concentration 
(F+R) 
CD49f 
TCTTGCCAGCAAGGTGT
AGC 
ACACGAACAATCCCTTTC
CAGT 
62 250 µM 
CD49b 
CGGGCAAATTATACCG
GCCA 
GGAGCCAATCTGGTCACC
TC 
62 250 µM 
CD44 TCAATGCTTCAGCTCCACC
T 
TTTCTGGACATAGCGGGT
GC 
62 250 µM 
CD24 
GCTCCTACCCACGCAG
ATTT 
GCCTTGGTGGTGGCATTA
GT 
62 250 µM 
POU5F1 
AGTGAGAGGCAACCTG
GAGA 
CTCGGACCACATCCTTCT
CG 
62 250 µM 
SOX2 
CATGAAGGAGCACCCG
GATT 
CTCGCCATGCTATTGCCG 62 250 µM 
 
 
 
Supplementary Table II – Summary of patient population 
Patient no. Age Gleason score PSA Staging 
P1 69 7 (3+4) 17,6 pT2cN0M0R0 
P2 68 7 (3+4) 8,55 pT2cNxM0R0 
P3
 
71 7 (4+3) 3,77 pT2aNxM0R0 
P4
 
64 7 (4+3) 4,63 pT2cNxM0R0 
P5 62 8 (3+5) Undetectable pT3aN0M0R0 
P6
 
57 9 (4+5) 75 pT3aN1M0R1 
P7 56 9 (4+5) 48,4 pT3bN0MxR1 
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